Ideaya Biosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
13analysts covering
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Darovasertib Registrational Trial Progress (OptimUM-02) Quarterly13,000.0%Target: 313 patients enrolled
Total Liquidity (Cash, Cash Equivalents, and Marketable Securities) Quarterly973MTarget: Maintain runway into 2030
IDE892 (PRMT5) Phase 1 Dose Escalation & Combination Cohort Initiation QuarterlyTarget: Initiate combination cohort with IDE397 in mid-2026
Watch Items
- Darovasertib NDA Submission under RTOR ProgramTrigger: Initiation of rolling NDA submission based on OptimUM-02 trial dataAction: Monitor FDA acceptance, review timelines, and commercial launch readiness activities
- Clinical Data Updates for IDE849 and IDE034Trigger: Release of Phase 1/2 clinical data updates by end of 2026Action: Evaluate safety, tolerability, and efficacy signals to validate the TOP1 ADC pipeline
- Cash Burn Rate and Dilution RiskTrigger: Quarterly cash burn exceeding historical averages or additional secondary offeringsAction: Re-assess cash runway projections and update valuation models for share dilution
Research as of 19 Jun 2026